Pipeline

We have two clinical programs for relugolix combination therapy which consisted of four international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2) and two in women with endometriosis-associated pain (SPIRIT 1 & 2).

We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, as a potential trigger of egg maturation in women undergoing assisted reproduction, including in vitro fertilization (IVF).

Myovant Development

Relugolix Combination Therapy
Preclinical
Phase 1
Phase 2
Phase 3
NDA Submitted
FDA Approved

Symptoms of Uterine Fibroids

Combination Therapy

Combination Therapy:
Relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg
Projected Upcoming Data Release:
Randomized withdrawal study in Q1 2021.
Note:
MAA submitted in March 2020. NDA under review with a FDA target action date of June 1, 2021.

Symptoms of Endometriosis

Combination Therapy

Combination Therapy:
Relugolix 40 mg + estradiol 1.0 mg and norethindrone acetate 0.5 mg
Projected Upcoming Data Release:
Long-term extension study in Q1 2021.
Note:
Positive data from replicate Phase 3 studies reported in April and June 2020.
MVT-602
Preclinical
Phase 1
Phase 2
Phase 3
NDA Submitted
FDA Approved

Female Infertility as Part of Assisted Reproduction

Japanese Development

Learn more about our clinical trials

We cannot achieve our mission to redefine care for women and for men without clinical trials. All across the world, patients, families, physicians, and clinics support these trials as we strive to turn our purpose-driven science into empowering medicines.

View clinical trials